GSK3B and renal fibrosis: Similarly, inhibiting AKT activation and GSK-3β phosphorylation may attenuate EMT-related E-cadherin inhibition, α-SMA elevation, and morphological transformation into a myofibroblast-like phenotype, thereby ameliorating proteinuria-induced tubular EMT and ultimately reducing renal fibrosis 12.